Red Queen Therapeutics is a clinical-stage company working to deliver treatment options for a broad range of virus-borne illnesses including influenzas, coronaviruses, and other current and emerging pathogens.

Red Queen Therapeutics

Thanks to Rowan Walrath for her expert reporting in this feature story in American Chemical Society's Chemical & Engineering News.

Thanks to Frank Vinluan and MedCity News for the very informative writeup of our company and its platform.

https://lnkd.in/g-jkxcHH

Today we are thrilled to formally "unstealth." With $55M in Series A funding from ATP (Apple Tree Partners), clinical proof-of-concept for our novel antiviral platform, and a terrific team, we are excited about continuing our progress on behalf of patients!

https://lnkd.in/ek5dGznq

Congratulations to our portfolio company Aethon Therapeutics on their significant multi-year collaboration with Revolution Medicines! Under the agreement, Aethon will create novel antibodies to home in on cancer neoantigens generated by treatment with Revolution Medicines RAS inhibitors.

https://lnkd.in/eSRG3YYs

We're excited to be sharing Phase 1 clinical trial results for our lead program RQ-01 in a poster session at the American Society for Microbiology #ASMicrobe conference this Sunday, June 16, 10:30-11:30 am! The results – which show promising signs of efficacy and proof-of-concept for Red Queen’s novel anti-viral platform along with placebo-like levels of safety – will be presented by Dr. Shyam Kottilil, one of the trial investigators. Stop by to learn more! #ASM2024 #ASMMicrobe2024

Congratulations to the Red Queen team for enrolling the first subject in a randomized placebo-controlled clinical study to examine the effects of its investigational intranasal fusion inhibitor (RQ-01) in low-risk COVID-19 subjects. 

RQ-01 may help treat COVID-19, regardless of variant, in populations of unmet medical need.
 
https://lnkd.in/gHq2dkxY

REDQ

COM:REDQUEENTX

Red Queen Therapeutics